Classes
Publications
- Alirocumab, Praluent(R) in the light of studies2016 | First Faculty of Medicine
- Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia2010 | First Faculty of Medicine
- Clinical studies, evidence based medicina expectations and reality2009 | First Faculty of Medicine
- Treatment of HLP and DLP in 20092009 | First Faculty of Medicine
- Pravastatin and its place in therapy of dyslipidemia in 20102009 | First Faculty of Medicine
- Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Jistoty a nejistoty na křižovatkách současné medicíny2023 | First Faculty of Medicine
- Slibný perorální inhibitor PCSK9 ve vývoji2023 | First Faculty of Medicine
- Internista2023 | First Faculty of Medicine
- Vitamin B12 deficiency: a continent hidden from the eyes of diabetologists2023 | First Faculty of Medicine
Loading network view...
